A Neoadjuvant, Randomized, Phase II Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection

Trial Profile

A Neoadjuvant, Randomized, Phase II Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Mar 2017 Planned End Date changed from 1 Jan 2017 to 15 Aug 2018.
    • 06 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 01 Aug 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top